158 related articles for article (PubMed ID: 38031840)
21. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry.
Duell PB; Gidding SS; Andersen RL; Knickelbine T; Anderson L; Gianos E; Shrader P; Kindt I; O'Brien EC; McCann D; Hemphill LC; Ahmed CD; Martin SS; Larry JA; Ahmad ZS; Kullo IJ; Underberg JA; Guyton J; Thompson P; Wilemon K; Roe MT; Rader DJ; Cuchel M; Linton MF; Shapiro MD; Moriarty PM; Knowles JW
Atherosclerosis; 2019 Oct; 289():85-93. PubMed ID: 31487564
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
[TBL] [Abstract][Full Text] [Related]
23. Past, Present, and Future of Familial Hypercholesterolemia Management.
Rocha VZ; Santos RD
Methodist Debakey Cardiovasc J; 2021; 17(4):28-35. PubMed ID: 34824679
[TBL] [Abstract][Full Text] [Related]
24. Familial Hypercholesterolemia Identification Algorithm in Patients with Acute Cardiovascular Events in A Large Hospital Electronic Database in Bulgaria: A Call for Implementation.
Petrov I; Postadzhiyan A; Vasilev D; Kasabov R; Tokmakova M; Nikolov F; Istatkov V; Zhao B; Mutafchiev D; Petkova R
Adv Ther; 2021 May; 38(5):2323-2338. PubMed ID: 33754300
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular risk factor profiles in familial hypercholesterolemia patients with and without genetic mutation compared to a nationally representative sample of adults in a high-risk European country.
Chlebus K; Zdrojewski T; Gruchała M; Gałąska R; Pajkowski M; Kocejko MR; Chmara M; Pencina MJ
Am Heart J; 2019 Dec; 218():32-45. PubMed ID: 31706143
[TBL] [Abstract][Full Text] [Related]
26. Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events.
D'Erasmo L; Minicocci I; Di Costanzo A; Pigna G; Commodari D; Ceci F; Montali A; Brancato F; Stanca I; Nicolucci A; Ascione A; Galea N; Carbone I; Francone M; Maranghi M; Arca M
J Am Heart Assoc; 2021 May; 10(9):e018932. PubMed ID: 33890476
[TBL] [Abstract][Full Text] [Related]
27. Effect of Cumulative Exposure to Low-Density Lipoprotein-Cholesterol on Cardiovascular Events in Patients With Familial Hypercholesterolemia.
Tada H; Okada H; Nohara A; Yamagishi M; Takamura M; Kawashiri MA
Circ J; 2021 Oct; 85(11):2073-2078. PubMed ID: 34011825
[TBL] [Abstract][Full Text] [Related]
28. Metabolic systems approaches update molecular insights of clinical phenotypes and cardiovascular risk in patients with homozygous familial hypercholesterolemia.
Du Z; Li F; Jiang L; Li L; Du Y; Yu H; Luo Y; Wang Y; Sun H; Hu C; Li J; Yang Y; Jiao X; Wang L; Qin Y
BMC Med; 2023 Jul; 21(1):275. PubMed ID: 37501168
[TBL] [Abstract][Full Text] [Related]
29. Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol.
Zhang Y; Dron JS; Bellows BK; Khera AV; Liu J; Balte PP; Oelsner EC; Amr SS; Lebo MS; Nagy A; Peloso GM; Natarajan P; Rotter JI; Willer C; Boerwinkle E; Ballantyne CM; Lutsey PL; Fornage M; Lloyd-Jones DM; Hou L; Psaty BM; Bis JC; Floyd JS; Vasan RS; Heard-Costa NL; Carson AP; Hall ME; Rich SS; Guo X; Kazi DS; de Ferranti SD; Moran AE
JAMA Cardiol; 2024 Mar; 9(3):263-271. PubMed ID: 38294787
[TBL] [Abstract][Full Text] [Related]
30. Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease.
Hedegaard BS; Bork CS; Kaltoft M; Klausen IC; Schmidt EB; Kamstrup PR; Langsted A; Nordestgaard BG
J Am Coll Cardiol; 2022 Nov; 80(21):1998-2010. PubMed ID: 36396201
[TBL] [Abstract][Full Text] [Related]
31. Clinical Features and Gaps in the Management of Probable Familial Hypercholesterolemia and Cardiovascular Disease.
Zafrir B; Jubran A; Lavie G; Halon DA; Flugelman MY; Shapira C
Circ J; 2017 Dec; 82(1):218-223. PubMed ID: 28701632
[TBL] [Abstract][Full Text] [Related]
32. Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry.
Kayıkcioglu M; Başaran Ö; Doğan V; Mert KU; Mert GÖ; Özdemir İH; Rencüzoğulları İ; Karadeniz FÖ; Tekinalp M; Aşkın L; Demirelli S; Gencer E; Bekar L; Aktaş M; Resulzade MM; Kalçık M; Aksan G; Cinier G; Akay KH; Pekel N; Utku Şenol ; Demir V; İnci S; Derviş E; Özlek B; Özlek E; Çelik O; Çil C; Biteker M
J Clin Lipidol; 2023; 17(6):732-742. PubMed ID: 38072583
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
[TBL] [Abstract][Full Text] [Related]
34. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
[TBL] [Abstract][Full Text] [Related]
35. Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
Pasta A; Cremonini AL; Formisano E; Fresa R; Bertolini S; Pisciotta L
Atherosclerosis; 2020 Sep; 308():6-14. PubMed ID: 32771803
[TBL] [Abstract][Full Text] [Related]
36. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
[TBL] [Abstract][Full Text] [Related]
37. Association between Achilles Tendon Softness and Atherosclerotic Cardiovascular Disease in Patients with Familial Hypercholesterolemia.
Michikura M; Ogura M; Hori M; Matsuki K; Makino H; Hosoda K; Harada-Shiba M
J Atheroscler Thromb; 2022 Nov; 29(11):1603-1612. PubMed ID: 35013021
[TBL] [Abstract][Full Text] [Related]
38. Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH.
Anagnostis P; Rizos CV; Skoumas I; Rallidis L; Tziomalos K; Skalidis E; Kotsis V; Doumas M; Kolovou G; Sfikas G; Garoufi A; Lambadiari V; Dima I; Kiouri E; Agapakis D; Zacharis E; Antza C; Kolovou V; Koumaras C; Bantouvakis G; Liamis G; Liberopoulos EN
Endocrine; 2022 May; 76(2):324-330. PubMed ID: 35262845
[TBL] [Abstract][Full Text] [Related]
39. Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.
Miname MH; Bittencourt MS; Nasir K; Santos RD
Curr Opin Lipidol; 2019 Apr; 30(2):82-87. PubMed ID: 30649025
[TBL] [Abstract][Full Text] [Related]
40. Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia.
Paquette M; Bernard S; Ruel I; Blank DW; Genest J; Baass A
J Clin Lipidol; 2019; 13(1):123-128. PubMed ID: 30318454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
